loops7/E+ via Getty Images
Adamis Pharmaceuticals (ADMP) has been a “Story Stock” a couple of times with its epinephrine product, SYMJEPI, and its naloxone candidate, ZIMHI. SYMJEPI was supposed to be the answer to the notoriously over-priced Epi-Pen by…

Click here to view the original article.